Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 10/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495322 | 0.80 | TDP1 (0.46) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL8491593 | 0.80 | ERN1 (0.43) | TDP1ERN1MEN1LMNATHRB | |
| SCHEMBL659120 | 0.80 | ERN1 (0.43) | TDP1ERN1MEN1LMNATHRB | |
| SCHEMBL29654634 | 0.80 | ERN1 (0.43) | TDP1ERN1MEN1LMNATHRB | |
| SCHEMBL15514624 | 0.78 | TDP1 (0.45) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL3842233 | 0.78 | TDP1 (0.45) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL29954698 | 0.75 | TDP1 (0.42) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL21121085 | 0.75 | TDP1 (0.42) | TDP1ERN1HSD17B10MEN1LMNA | |
| SCHEMBL19948618 | 0.75 | ERN1 (0.39) | TDP1ERN1MEN1LMNATHRB | |
| SCHEMBL7045902 | 0.75 | ERN1 (0.48) | TDP1ERN1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | TDP1 2779/4885ERN1 816/4885HSD17B10 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.